search
Back to results

Innovations in Dementia Empowerment and Action (IDEA)

Primary Purpose

Alzheimer Disease, Dementia, Mild Cognitive Impairment

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Innovations in Dementia Empowerment and Action (IDEA)
Reducing Disabilities in Alzheimer's Disease (RDAD)
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer Disease focused on measuring LGBT

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for care receiver

  • Age at enrollment is 50 years of age or older
  • Have dementia, (e.g., Alzheimer's disease, MCI, Vascular dementia, Parkinson's disease, Lewy Body dementia) or memory loss significant enough to affect daily activities
  • Living in the community, not in a care facility.
  • Living in the U.S.
  • Either the care receiver or care giver must self-identify as LGBT (or sexual or gender non-binary or same sex sexual behavior)

Inclusion criteria for care giver

  • Provide care to the care recipient with dementia.
  • Willing to spend 30 minutes daily for study activities (or coordinate for someone to.)
  • Unpaid
  • Live in the community, not in a care facility
  • Living in the U.S.

Neither care receiver nor caregiver:

  • Has known terminal illness (with death anticipated within the next 12 months)
  • Was hospitalized for a psychiatric disorder in the 12 months prior to baseline
  • Is currently suicidal or having major hallucinations or delusions
  • Plans to move to long term care setting within 6 months of enrollment.
  • Has any physical limitations/chronic conditions preventing participation in an exercise program.

Sites / Locations

  • University of Washington

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard intervention

Personalized intervention

Arm Description

Reducing Disabilities in Alzheimer's Disease (RDAD): 9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months

Innovations in Dementia Empowerment and Action (IDEA): 9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months

Outcomes

Primary Outcome Measures

Change in Physical Activity of Care Recipient
Days exercise >= 30 min in the past week
Change in Physical Activity of Caregiver
Days exercise >= 30 min in the past week
Change in Physical Functioning of Care Recipient
Medical outcomes study short form (MOS SF-36)
Change in Physical Functioning of Caregiver
Medical outcomes study short form (MOS SF-36)
Change in Perceived Stress (PSS) of Caregiver
14-item self-report measure designed to measure nonspecific, appraised stress during the past month

Secondary Outcome Measures

Change in Depressive Symptomatology of Caregiver
CESD-10
Change in Quality of Life (QOL-AD) of Care Recipient
QOL-AD measure
Change in Rate of Care-Recipient Behavioral Disturbances
Revised Memory and Behavior Problem Checklist (RMBPC) assess presence and frequency of memory, depressive, disruptive behavior and caregiver response

Full Information

First Posted
April 6, 2018
Last Updated
September 13, 2023
Sponsor
University of Washington
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT03550131
Brief Title
Innovations in Dementia Empowerment and Action
Acronym
IDEA
Official Title
Aging With Pride: Innovations in Dementia Empowerment and Action
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
December 5, 2018 (Actual)
Primary Completion Date
May 16, 2023 (Actual)
Study Completion Date
May 16, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
Collaborators
National Institute on Aging (NIA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem. Caregiving of sexual/gender minority older adults with AD/RD is of concern due to social stigma, marginalization, and isolation, which may be barriers to sustaining caregiving. It is necessary and timely to translate evidence-based culturally adaptable interventions for this underserved and stigmatized population. Reducing Disability in Alzheimer's Disease (RDAD) has been evaluated in a randomized controlled trial and has shown to successfully train community-dwelling CR (care receiver)-CG dyads to increase the physical activity and functioning of individuals with AD/RD and their CGs and to teach CGs techniques for managing behavioral symptoms of CRs. RDAD consequently decreases stress of CGs, delays institutionalization of CRs, and increases health related quality of life (HRQOL) of CRs and CGs. Thus, this study will evaluate the effect of the standard RDAD among lesbian, gay, bisexual, and transgender (LGBT) CRs with AD/RD and their CGs, and this study will test a personalized intervention tailored to better respond to distinct risks experienced by CGs and LGBT CRs with AD/RD, addressing unique sexual/gender minority CG risk factors (e.g., identity management, stigma-related adverse or traumatic life events, and lack of social support).
Detailed Description
We will address the following aims: Aim 1. Test the translation and enhancement of intervention designed to increase physical activities of older adult care receivers (CRs) with AD/RD and their CGs. Aim 2. Evaluate the short- and long-term effect of the standard and personalized intervention on primary (physical activity and functioning; perceived stress for CGs; independence/residential status (institutionalization) for CRs) and secondary outcomes (HRQOL; depressive symptomatology; behavioral disturbances for CRs). Aim 3. Test the moderating roles of CR-CG characteristics, including type of CR-CG relationship, sex, and severity of CR AD/RD, on the treatment effect of the standard and personalized intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia, Lewy Body Dementia, Vascular Dementia
Keywords
LGBT

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This study will utilize a 2-group randomized controlled trial design including 2 pre-intervention and 4 post-intervention assessments. The comparator group (standard intervention) will have 112 caregiver-care receiver dyads, and the experimental group (personalized intervention) will have 113 caregiver-care receiver dyads.
Masking
Participant
Masking Description
Participants receiving intervention will not be informed whether it is the standard or personalized treatment.
Allocation
Randomized
Enrollment
322 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard intervention
Arm Type
Active Comparator
Arm Description
Reducing Disabilities in Alzheimer's Disease (RDAD): 9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months
Arm Title
Personalized intervention
Arm Type
Experimental
Arm Description
Innovations in Dementia Empowerment and Action (IDEA): 9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months
Intervention Type
Behavioral
Intervention Name(s)
Innovations in Dementia Empowerment and Action (IDEA)
Other Intervention Name(s)
Personalized RDAD
Intervention Description
The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
Intervention Type
Behavioral
Intervention Name(s)
Reducing Disabilities in Alzheimer's Disease (RDAD)
Other Intervention Name(s)
Standard RDAD
Intervention Description
The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
Primary Outcome Measure Information:
Title
Change in Physical Activity of Care Recipient
Description
Days exercise >= 30 min in the past week
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Title
Change in Physical Activity of Caregiver
Description
Days exercise >= 30 min in the past week
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Title
Change in Physical Functioning of Care Recipient
Description
Medical outcomes study short form (MOS SF-36)
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Title
Change in Physical Functioning of Caregiver
Description
Medical outcomes study short form (MOS SF-36)
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Title
Change in Perceived Stress (PSS) of Caregiver
Description
14-item self-report measure designed to measure nonspecific, appraised stress during the past month
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Secondary Outcome Measure Information:
Title
Change in Depressive Symptomatology of Caregiver
Description
CESD-10
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Title
Change in Quality of Life (QOL-AD) of Care Recipient
Description
QOL-AD measure
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months
Title
Change in Rate of Care-Recipient Behavioral Disturbances
Description
Revised Memory and Behavior Problem Checklist (RMBPC) assess presence and frequency of memory, depressive, disruptive behavior and caregiver response
Time Frame
Baseline, 6 weeks, 13 weeks, 30 weeks, 13 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for care receiver Age at enrollment is 50 years of age or older Have dementia, (e.g., Alzheimer's disease, MCI, Vascular dementia, Parkinson's disease, Lewy Body dementia) or memory loss significant enough to affect daily activities Living in the community, not in a care facility. Living in the U.S. Either the care receiver or care giver must self-identify as LGBT (or sexual or gender non-binary or same sex sexual behavior) Inclusion criteria for care giver Provide care to the care recipient with dementia. Willing to spend 30 minutes daily for study activities (or coordinate for someone to.) Unpaid Live in the community, not in a care facility Living in the U.S. Neither care receiver nor caregiver: Has known terminal illness (with death anticipated within the next 12 months) Was hospitalized for a psychiatric disorder in the 12 months prior to baseline Is currently suicidal or having major hallucinations or delusions Plans to move to long term care setting within 6 months of enrollment. Has any physical limitations/chronic conditions preventing participation in an exercise program.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen Fredriksen-Goldsen, PhD
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Innovations in Dementia Empowerment and Action

We'll reach out to this number within 24 hrs